ALPN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALPN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:
We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.
Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
As of today (2024-06-05), Alpine Immune Sciences's share price is $64.97. Alpine Immune Sciences's GF Value is $11.17. Therefore, Alpine Immune Sciences's Price-to-GF-Value for today is 5.82.
Based on the relationship between the current stock price and the GF Value, GuruFocus believes Alpine Immune Sciences is Significantly Overvalued.
Alpine Immune Sciences (NAS:ALPN) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:
Posssible Evaluations | All-in-One Screener Examples (2) |
Possible Value Trap, Think Twice (1) | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (3) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (3) | Predictable High Quality Companies which are Significantly Undervalued |
(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) There is only a sufficient margin of safety when the stock is undervalued.
Alpine Immune Sciences's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 64.97 | / | 11.17 | |
= | 5.82 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Alpine Immune Sciences's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Mitchell Gold | director, officer: Executive Chairman and CEO | ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102 |
Peter A. Thompson | director | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
James Paul Rickey | officer: Senior VP and CFO | ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102 |
Xiangmin Cui | director, 10 percent owner | NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000 |
Wolfgang Dummer | officer: Chief Medical Officer | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Remy Durand | officer: Chief Business Officer | C/O ALPINE IMMUNE SCIENCES, INC., 185 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98012 |
Jorn Drappa | director | C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878 |
Andrew Seth Sandler | officer: Chief Medical Officer | 1301 2ND AVE, SEATTLE WA 98101 |
Frazier Life Sciences Viii, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Robert E Conway | director | C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021 |
Christopher Peetz | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080 |
Decheng Capital China Life Sciences Usd Fund Iii, L.p. | 10 percent owner | UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104 |
Alpine Immunosciences, L.p. | 10 percent owner | 600 STEWART STREET, SUITE 1503, SEATTLE WA 98101 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Business Wire • 11-13-2023
By Business Wire Business Wire • 11-22-2022
By Business Wire • 09-05-2023
By Business Wire • 11-07-2023
By Business Wire • 10-13-2023
By Business Wire Business Wire • 05-19-2023
By Business Wire Business Wire • 11-07-2022
By Business Wire Business Wire • 02-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.